NBE Therapeutics
Gerd Munzert serves as Chief Clinical Officer of NBE Therapeutics since June 2021. Gerd is a hematologist and medical oncologist with more than 20 years of experience in anticancer drug development.
Gerd has worked in different roles for Boehringer Ingelheim Oncology. He successfully led and steered the clinical development of NCEs such as antimitotic kinases, EGFR tyrosine kinases, and other targeted agents. In addition to his role at NBE Therapeutics, he maintains his affiliation with BI Oncology with responsibility for preclinical and early clinical compounds, translational programs, and external collaborations.
He attended medical school in Freiburg and Munich and did postdoctoral research at the University of Michigan, working on G-protein receptors in the lab of Prof. T. Yamada. In his further academic career, he focused on the pathophysiology and treatment of leukemias and lymphomas at Ulm University where he maintains an affiliation as a lecturer.
This person is not in any offices
NBE Therapeutics
1 followers
NBE-Therapeutics is developing best-in-class cancer therapies to increase survival and improve quality of life for cancer patients worldwide. The company’s next-generation immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate (ADC) platform. This best-in-class ADC platform creates highly potent and safe immune-stimulatory ADCs ("iADCs™") with an anthracycline payload, not only directly targeting tumor cells, but also inducing a long-lasting immunological anti-tumor effect. The company’s lead asset, NBE-002, an anti-ROR1 ADC, is due to start first-in-human clinical trials in three US centers by the end of 2020, focusing on triple negative breast cancer, but also other solid cancer indications which express ROR1. NBE-Therapeutics is a privately owned biotech company based in Basel, financed by Germany’s Boehringer Ingelheim Venture Fund, the Czech Republic’s PPF Group and Denmark’s Novo Holdings as international institutional investors, and by Swiss, German, and Dutch private investors. The company has raised over USD 65m, including a USD 22m Series C (2020), two USD 20m Series B rounds (2016 & 2018), a USD 3m Series A (2015), and over USD 4m from several non-dilutive grants from organizations including the Swiss Commission for Technology & Innovation, the European Commission, and Systems-X.